Preclinical News and Research

RSS

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Critical Pharmaceuticals to develop hGH nasal spray

Critical Pharmaceuticals, the speciality pharmaceuticals company, today announced that it had secured a £1.5m translation award from the Wellcome Trust to develop a nasal spray of Human Growth Hormone (hGH) using its proprietary CriticalSorb technology as an alternative to injection.

15 Oct 2009

Commonwealth Biotechnologies to acquire GL Biochem

Commonwealth Biotechnologies, Inc. has recently announced a definitive share purchase agreement to acquire Shanghai-based GL Biochem and associated businesses (the “GL Group”), the largest global supplier of research-grade peptide products and peptide reagents.

15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Elsevier Business Intelligence and Windhover Conferences have announced a major addition to the lineup for their upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. In Roche and Genentech: Understanding Their Collaborative Business Development Model, the two executives who designed and implemented the radical new collaborative business model will share exactly how they make this relationship work and the outlook for the business model in the future.

14 Oct 2009

New non-invasive technology to measure glucose levels in the human eye

New non-invasive technology designed to painlessly measure glucose levels in the human eye shows promise of one day replacing the finger-stick blood test, according to results of a pre-clinical study funded by Freedom Meditech, Inc.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.

14 Oct 2009

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Champions Biotechnology, Inc., a drug development company with a preclinical platform able to predict clinical effectiveness, accelerate development and enhance the value of oncology drugs, today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410.

14 Oct 2009

Older generation antibiotic for treating colon cancer

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages ― and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

14 Oct 2009

Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis

Galapagos NV announced today that it has expanded its global strategic alliance in metabolic diseases with an affiliate of Merck & Co., Inc to incorporate the development of new therapies for atherosclerosis.

14 Oct 2009

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.

14 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

SANUWAVE, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.

13 Oct 2009

SAFC Pharma expands contract manufacturing services

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced the completion of an addition to its Carlsbad, Calif., facility that expands the Company's contract manufacturing services for its late phase and commercial clients.

13 Oct 2009

Cognitive abilites other than memory may decline prior to clinical diagnosis in patients with Alzheimer's disease

Cognitive abilities other than memory, including visuospatial skills needed to perceive relationships between objects, may decline years prior to a clinical diagnosis in patients with Alzheimer's disease, according to a report in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

13 Oct 2009

Ethicon Endo-Surgery launches energy delivery devices at the 95th ACS Annual Clinical Congress

Ethicon Endo-Surgery, Inc., today unveiled its broad portfolio of energy delivery devices at the 95th Annual Clinical Congress of the American College of Surgeons (ACS).

12 Oct 2009

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Raptor Pharmaceutical Corp., announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.

12 Oct 2009

Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

Selexis SA and Irvine Scientific Inc. announced today plans to jointly present results of a recent collaborative effort combining the Selexis SURE Cell Line Development Programs(TM) and the Irvine IS CHO Culture System, demonstrating the rapid production of gram quantities of monoclonal antibodies from stable CHO production cell lines.

12 Oct 2009

Preclinical News and Research

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Critical Pharmaceuticals to develop hGH nasal spray

Commonwealth Biotechnologies to acquire GL Biochem

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

New non-invasive technology to measure glucose levels in the human eye

Breakthrough in pancreatic cancer treatment

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Older generation antibiotic for treating colon cancer

Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

Sequella receives Phase 1 SBIR grant for developing SQ641

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

SAFC Pharma expands contract manufacturing services

Cognitive abilites other than memory may decline prior to clinical diagnosis in patients with Alzheimer's disease

Ethicon Endo-Surgery launches energy delivery devices at the 95th ACS Annual Clinical Congress

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics